Drugs / ABSK-011
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07700953 | Jul → Aug 2026 overdue | — | Abbisko Therapeutics Co, Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06896760 | Apr → Nov 2025 overdue | — | Abbisko Therapeutics Co, Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06306872 | Feb 2024 → Sep 2025 | — | Abbisko Therapeutics Co, Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04906434 | Feb 2020 → Dec 2027 expected | liver cancer | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07327034 | Jun 2025 → Jun 2027 expected | hepatocellular carcinoma | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06978933 | Apr 2025 → Dec 2026 expected | hepatocellular carcinoma | RenJi Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05441475 | Dec 2021 → Dec 2028 expected | hepatocellular carcinoma | Abbisko Therapeutics Co, Ltd | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABSK-011 | “Participants will receive a single oral administration of approximately 200 mg/120 µCi \[14C\]ABSK-011 suspension after a low-fat breakfast on day 1 morning.” NCT06896760 ↗ |
| Action | Inhibit | “selective FGFR4 inhibitor” NCT06978933 ↗ |
| Route | Oral | “administration of oral ABSK-011” NCT04906434 ↗ |
| Target | FGFR4 | “selective FGFR4 inhibitor” NCT06978933 ↗ |